Patents Assigned to Dharmacon, Inc.
-
Patent number: 8415466Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: GrantFiled: April 30, 2012Date of Patent: April 9, 2013Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Patent number: 8399654Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.Type: GrantFiled: May 8, 2012Date of Patent: March 19, 2013Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20130059760Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1.Type: ApplicationFiled: October 1, 2012Publication date: March 7, 2013Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 8367318Abstract: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster. MiRNA inhibitors are described that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer. The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-?B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-?B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression.Type: GrantFiled: July 21, 2008Date of Patent: February 5, 2013Assignee: Dharmacon, Inc.Inventors: Anja Smith, Scott Baskerville, Devin Leake, Annaleen Vermeulen, Barbara Robertson, Anastasia Khvorova
-
Publication number: 20130023446Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.Type: ApplicationFiled: September 13, 2012Publication date: January 24, 2013Applicant: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120322855Abstract: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.Type: ApplicationFiled: July 19, 2012Publication date: December 20, 2012Applicant: DHARMACON, INC.Inventors: Christina Yamada, Anastasia Khvorova, Robert J. Kaiser, Emily Anderson, Devin Leake
-
Patent number: 8314229Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.Type: GrantFiled: November 8, 2010Date of Patent: November 20, 2012Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120283311Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.Type: ApplicationFiled: July 5, 2012Publication date: November 8, 2012Applicant: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120283142Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.Type: ApplicationFiled: July 18, 2012Publication date: November 8, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 8304528Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1.Type: GrantFiled: December 3, 2009Date of Patent: November 6, 2012Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120270926Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.Type: ApplicationFiled: June 28, 2012Publication date: October 25, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120270751Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.Type: ApplicationFiled: July 2, 2012Publication date: October 25, 2012Applicant: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 8293887Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.Type: GrantFiled: July 1, 2011Date of Patent: October 23, 2012Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120264813Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.Type: ApplicationFiled: June 25, 2012Publication date: October 18, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120259001Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.Type: ApplicationFiled: April 30, 2012Publication date: October 11, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Devin Leake, Barbara Robertson, Annaleen Vermeulen, Christina Yamada
-
Publication number: 20120258889Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.Type: ApplicationFiled: June 15, 2012Publication date: October 11, 2012Applicant: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120258888Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.Type: ApplicationFiled: June 12, 2012Publication date: October 11, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120252873Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.Type: ApplicationFiled: June 6, 2012Publication date: October 4, 2012Applicant: DHARMACON, INC.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Publication number: 20120245219Abstract: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are substantially complementary to one or more mature miRNAs or piRNAs.Type: ApplicationFiled: June 7, 2012Publication date: September 27, 2012Applicants: DHARMACON, INC., ELITECH HOLDING B.V.Inventors: Anastasia Khvorova, Annaleen Vermeulen, Rob Kaiser, Jon Karpilow, Nicolaas M.J. Vermeulen, Walt Mahoney
-
Patent number: 8273722Abstract: Compositions, kits, systems, equipment, and protocols utilize synthetic siRNA having a delivery facilitating moiety in improved bioprocesses that enhance the production of biomaterials. The siRNA can target genes associated with the following: 1) deleterious vector derived genes; 2) genes that confer non-optimal growth or differentiation properties to the cells; 3) genes that can influence heterogeneity or post-translational modification pattern of the desirable gene product; 4) genes that highly express non-desired proteins; 5) genes that express proteins which interfere with purification of the desired protein; and 6) other genes that can interfere with the bioprocess.Type: GrantFiled: July 11, 2008Date of Patent: September 25, 2012Assignee: Dharmacon, Inc.Inventors: James R. Ladine, William S. Marshall, Yuriy Fedorov, Christina Yamada